<code id='454A2CA777'></code><style id='454A2CA777'></style>
    • <acronym id='454A2CA777'></acronym>
      <center id='454A2CA777'><center id='454A2CA777'><tfoot id='454A2CA777'></tfoot></center><abbr id='454A2CA777'><dir id='454A2CA777'><tfoot id='454A2CA777'></tfoot><noframes id='454A2CA777'>

    • <optgroup id='454A2CA777'><strike id='454A2CA777'><sup id='454A2CA777'></sup></strike><code id='454A2CA777'></code></optgroup>
        1. <b id='454A2CA777'><label id='454A2CA777'><select id='454A2CA777'><dt id='454A2CA777'><span id='454A2CA777'></span></dt></select></label></b><u id='454A2CA777'></u>
          <i id='454A2CA777'><strike id='454A2CA777'><tt id='454A2CA777'><pre id='454A2CA777'></pre></tt></strike></i>

          explore

          explore

          author:Wikipedia    Page View:126
          The FDA building -- First Opinion coverage from STAT
          Adobe

          The Food and Drug Administration said Monday that it has deep reservations about NurOwn, an investigational ALS treatment from BrainStorm Cell Therapeutics, citing a lack of evidence that the medicine works and the company’s failure to demonstrate that it can properly manufacture the product.

          In documents disclosed ahead of a Wednesday public hearing on NurOwn’s application for approval, the FDA detailed its problems with a clinical trial that missed its primary objective and noted that BrainStorm submitted “grossly deficient” information on how the medicine is made, voicing “major concerns that the available data do not meet the statutory standard of substantial evidence of effectiveness to support” approval.

          advertisement

          BrainStorm filed for approval over the FDA’s protest, insisting that NurOwn has demonstrated benefits for a subset of ALS patients with milder disease. That conclusion, based on an after-the-fact analysis of the company’s failed pivotal trial, has proved polarizing among patients and physicians, with some arguing that the FDA should exercise flexibility in light of the irrevocably fatal nature of ALS and others demanding BrainStorm conduct another clinical trial to demonstrate its benefits.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more
          South Korea throws huge K
          South Korea throws huge K

          1:30AttendeesoftheWorldScoutJamboreewatchaK-PopconcertaftertheclosingceremonyoftheWorldScoutJamboree

          read more
          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more

          PBM executives asked to testify by House panel

          Rep.JamesComer(R-Ky.),thechairoftheHouseCommitteeonOversightandAccountability,hastakenaninterestinph